Revenue (Quarterly) Chart

View Revenue (Quarterly) for OMER.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 28.53M
March 31, 2026 9.893M
December 31, 2025 0.00
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.00
December 31, 2024 0.00
September 30, 2024 0.00
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.00
September 30, 2023 0.00
June 30, 2023 0.00
March 31, 2023 0.00
December 31, 2022 0.00
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 0.00
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 0.00
September 30, 2020 26.11M
June 30, 2020 13.53M
Date Value
March 31, 2020 23.54M
December 31, 2019 33.42M
September 30, 2019 29.86M
June 30, 2019 26.75M
March 31, 2019 21.78M
December 31, 2018 22.02M
September 30, 2018 4.608M
June 30, 2018 1.655M
March 31, 2018 1.588M
December 31, 2017 13.76M
September 30, 2017 21.66M
June 30, 2017 17.15M
March 31, 2017 12.26M
December 31, 2016 12.90M
September 30, 2016 11.29M
June 30, 2016 10.00M
March 31, 2016 7.419M
December 31, 2015 6.675M
September 30, 2015 3.259M
June 30, 2015 3.187M
March 31, 2015 0.388M
December 31, 2014 0.18M
September 30, 2014 0.214M
June 30, 2014 0.045M
March 31, 2014 0.10M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
Eli Lilly & Co. 22.97B
Talphera, Inc. 0.00
Hyperion DeFi, Inc. 0.3577M
ANI Pharmaceuticals, Inc. 266.04M
Corcept Therapeutics, Inc. 256.15M